Ublituximab in children, Vidofludimus Calcium in progression, Glatirameracetat in PPMS? All three were a topic at the ACTRIMS Congress in February 2026.
Prof. Mathias Mäurer talks about the three active substances in this video.
And why one should not develop too much enthusiasm here yet: All three studies – for Ublituximab for children, the study is even still in planning – are still in their infancy, so to speak.
The three could nevertheless become interesting in the future. Prof. Mathias Mäurer provides information about the interim status and categorizes the goals of the preparations in a way that is understandable to patients:
Please activate the automated translation on YouTube.
This post was translated from German to English with the help of AI.
